The UK Competition Authority fines 3 pharmaceutical companies £2.3 million for having an anti-competitive agreement in the supply of the life-saving drug fludrocortisone and secures £8 million in damages for the National Health Service (Aspen / Amilco / Tiofarma)

Competition Authority, UK

Previous article The EU Commission fines two pharmaceutical companies €60.5 million for delaying the entry of cheaper generic medicine for sleep disorders (Teva / Cephalon) Next article The US District Court for the Northern District of Illinois dismisses antitrust case challenging patent thicket (Humira)

9 Jul 2020

The UK Competition Authority fines 3 pharmaceutical companies £2.3 million for having an anti-competitive agreement in the supply of the life-saving drug fludrocortisone and secures £8 million in damages for the National Health Service (Aspen / Amilco / Tiofarma)

KEYWORDS

Reference

UK Competition Authority, Aspen / Amilco / Tiofarma, Press Release, 9 July 2020

CMA levies fines of £2.3m and secures £8m for NHS in pharma probe* The CMA has formally concluded that 3 pharmaceutical companies took part in an illegal arrangement in relation to the supply of life-saving medicine. The investigation by the Competition and Markets

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

UK Competition Authority
UK Competition & Markets Authority - CMA (London)

United Kingdom 352 contributions 88466 visits

Quotation

UK Competition Authority, The UK Competition Authority fines 3 pharmaceutical companies £2.3 million for having an anti-competitive agreement in the supply of the life-saving drug fludrocortisone and secures £8 million in damages for the National Health Service (Aspen / Amilco / Tiofarma), 9 July 2020, e-Competitions Pay-for-delay agreements, Art. N° 95771

Visites 291